TARS
Tarsus·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TARS
Tarsus Pharmaceuticals, Inc.
A biopharmaceutical company that developing novel drugs used for the treatment of blepharitis
15440 Laguna Canyon Road, Suite 160, Irvine, California 92618
--
Tarsus Pharmaceuticals, Inc., was incorporated in November 2016 under the laws of the State of Delaware. The company is a late-stage clinical biopharmaceutical company dedicated to the development and commercialization of therapeutic drug candidates to address therapeutic options with limited initial market opportunities for ophthalmic diseases. The company's lead product candidate, TP-03, is a phase 2b/3 novel therapy currently under development for the treatment of blepharitis caused by Demodex, known as Demodex eye.
Earnings Call
Q1/2025
Estimate EPS-0.63
Actual EPS-0.64
Estimate Revenue71.62M
Actual Revenue78.34M
Tarsus Pharmaceuticals' Q1 2025 Earnings Call: Key Contradictions on DTC Campaign, Prescribing Dynamics, and Financial Projections
May 02,2025 07:32
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.36
Actual EPS-0.48
Estimate Revenue95.81M
Actual Revenue102.70M
Tarsus Pharmaceuticals Q2 2025: Key Contradictions on XDEMVY's Market Potential, Discount Strategies, and Seasonal Sales Trends
Aug 11,2025 07:17
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TARS has released its 2025 Q3 earnings. EPS was reported at -0.3, versus the expected -0.33, beating expectations. The chart below visualizes how TARS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TARS has released its 2025 Q3 earnings report, with revenue of 118.70M, reflecting a YoY change of 146.68%, and net profit of -12.59M, showing a YoY change of 46.26%. The Sankey diagram below clearly presents TARS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
